Neoplasms

All Conditions

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Immune System Diseases

Rare Diseases

Carcinoma

Adenocarcinoma

Recurrence

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Hypersensitivity

Cystadenocarcinoma, Serous

Fallopian Tube Neoplasms

Cystadenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Fallopian Tube Diseases

Neoplasms, Cystic, Mucinous, and Serous

Ovarian Cancer

Ovarian Epithelial Cancer

Fallopian Tube Cancer

Adenocarcinoma of the Appendix

Antineoplastic Agents

All Drugs and Chemicals

Apatinib

Angiogenesis Inhibitors

Fluzoparib

Poly(ADP-ribose) Polymerase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Fluzoparib capsule: oral administration, 3 capsules/dose (150 mg/ dose), twice a day, in the morning and evening, before/after meals can be taken orally, it is recommended to take orally within 0.5h after breakfast and dinner, continuous administration. Every 4 weeks is a treatment cycle.

Fluzoparib capsule: oral administration, 2 capsules/dose (100 mg/ dose), twice a day, in the morning and evening, before/after meals can be taken orally, it is recommended to take orally within 0.5h after breakfast and dinner, continuous administration. Every 4 weeks is a treatment cycle.

Apatinib: oral administration, 1 tablet/dose (375 mg/tablet), once a day, it is recommended to take orally within 0.5h after breakfast, continuous administration. Every 4 weeks is a treatment cycle.

Fluzoparib+Apatinib

Li Li

This is a randomized, multicenter, two-arm, noncomparative, phase II study of fluzoparib with or without apatinib for maintenance therapy in PARPi-pretreated platinum-sensitive recurrent ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib with or without apatinib.

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

A Randomized, Multicenter, Noncomparative Clinical Study of Fluzoparib With or Without Apatinib for Maintenance Therapy in PARPi-pretreated Platinum-sensitive Recurrent Ovarian Cancer

Time from the date of randomization to the date of first documented tumor progression or death due to any cause, whichever occurs first.

Time from the date of randomization to the date of death due to any cause.

ORR is the proportion of patients with best response of complete response (CR) and partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

the proportion of patients with a best overall response of confirmed complete or partial response or stable disease based on RECIST v1.1.

TFST is defined as the time from the randomization to the earliest of the date of anti-cancer therapy start date following study treatment discontinuation, or death.

TSST is defined as the time from the randomization to the earliest of the date of second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.

Time to treatment failure by RECIST v. 1.1 or CA-125 or death is defined as the time from the randomization to the date of RECIST progression or death by any cause, whichever occurs first.

Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.

Guangxi Medical University

Prof.

Behaviors and Mental Disorders

Fatigue

Carcinoma, Renal Cell

Kidney Neoplasms

Urologic Neoplasms

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Quality of Life

Renal Cell Carcinoma

Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic

Florence JOLY-LOBBEDEZ, PD

Longitudinal study nonrandomized, multicenter observational descriptive monitoring patients treated with anti-angiogenic for metastatic kidney cancer

Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer

Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer : a Pilot Study

Assessing the impact of fatigue, memory problems and attentional induced by an anti-angiogenic and study their evolution over time in patients with metastatic kidney cancer.

Studying the different parameters of quality of life and their evolution over time.

Studying the correlations between disorders of cognitive functions and parameters of quality of life and fatigue.

Search for biological disturbances may be related to fatigue and cognitive disorders.

Assessing the impact of anxiety and depression at the waning of treatment

Compare the list of symptoms considered important by the patient compared to those recorded in the medical record.

sess the impact on the sexuality of patients with the waning of treatment

Compare the impact on quality of life and cognition side effects of different antiangiogenic agents used

Hoffmann-La Roche

Centre Francois Baclesse

Pharmaceutical Solutions

Bevacizumab

Antineoplastic Agents, Immunological

Growth Inhibitors

Fluzoparib capsule: oral administration, 3 capsules/dose (150 mg/ dose), twice a day, in the morning and evening, before/after meals can be taken orally, it is recommended to take orally within 0.5h after breakfast and dinner, continuous administration. Every 3 weeks is a treatment cycle.

Bevacizumab injection: intravenous, 15 mg/kg, every 3 weeks for a treatment cycle until disease progression or intolerable toxicity, up to a total of 15 months.

Fluzoparib Capsules

Chunyan Lan

Chunyan Lan, MD&PhD

This is an open-label, multi-center Phase II study of fluzoparib combined with bevacizumab for maintenance therapy after first-line platinum-containing chemotherapy in patients with BRCA wild-type advanced ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib plus bevacizumab.

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

An Open, Multicenter, Exploratory Clinical Study of Fluzoparib in Combination With Bevacizumab for Maintenance Therapy After First-line Platinum-containing Chemotherapy in BRCA Wild-type Advanced Ovarian Cancer

Open collection of homologous recombination deficiency status (HRD) status was performed to assess the impact of HRD status on the efficacy of fluazoparib in combination with bevacizumab.

Time from the date of first study treatment administration to the date of first documented tumor progression or death due to any cause, whichever occurs first.

Time from the date of first study treatment administration to the date of death due to any cause.

TFST is defined as the time from the first study administration to the earliest of the date of anti-cancer therapy start date following study treatment discontinuation, or death.

TSST is defined as the time from the first study administration to the earliest of the date of second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.

Time to progression by RECIST v. 1.1 or CA-125 or death is defined as the time from the first study administration to the date of RECIST or CA-125 progression or death by any cause, whichever occurs first.

Determination of changes in PROs with EQ-5D-5L

Sun Yat-sen University

Carcinosarcoma

Mixed Tumor, Mullerian

Adenoma, Pleomorphic

Sarcoma

Neoplasms, Connective and Soft Tissue

Malignant Mixed Mullerian Tumor

Soft Tissue Sarcoma

Amino Acids

Pamiparib

Tyrosine Kinase Inhibitors

Tyrosine

Phase Ib:

A dose de-escalation schedule is used in the phase Ib dose finding part. Dose Level 1 (starting dose): pamiparib 40 mg administered orally twice daily (fixed dose) and surufatinib 250 mg administered orally once daily on a 21-day treatment cycle. If ≥2/6 patients experience a dose limiting toxicity (DLT), we will de-escalate to Dose Level 2: pamiparib 40 mg administered orally twice daily (fixed dose) and surufatinib 200 mg administered orally once daily on a 21-day treatment cycle. Approximately 3-12 patients will be enrolled in phase Ib study.

Phase II:

The phase II part will begin once the recommended phase 2 dose (RP2D) of surufatinib have been determined in the Phase Ib in order to assess antitumor activity of pamiparib and surufatinib combination. In phase II study, pamiparib 40 mg orally twice daily and surufatinib PR2D will be administered.

Surufatinib

Chunyan Lan, M.D.

A number of studies suggest that the combination of PARP inhibitors and antiangiogenic agents produce synergistic activities. Pamiparib is a small molecule inhibitor selectivity for both PARP1 and PARP2. Surufatinib is a novel small-molecule inhibitor that simultaneously targets tumor angiogenesis (via Vascular Endothelial Growth Factor Receptor \[VEGFR\]1, VEGFR 2, VEGFR3 and Fibroblast Growth Factor Receptor 1 \[FGFR1\]) and immune evasion (via Colony Stimulating Factor 1 Receptor \[CSF1R\]). In this trial, we aimed to evaluate the efficacy, safety and tolerability of pamiparib in combination with surufatinib in patients with platinum-resistant ovarian cancer who received prior PARP inhibitors.

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial

To identify the biomarkers, including but not limited to genomic, homologous recombination deficiency (HRD), that predict the efficacy of this study treatment.

MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a dose limiting toxicity (DLT) during the first cycles. DLT is defined as: grade 3 febrile neutropenia, grade 4 hematologic toxicities, and ≥ grade 3 non-hematologic toxicities that occurred within the first cycle of treatment with pamiparib and surufatinib.

Determine the RP2D of the pamiparib and surufatinib combination

Proportion of patients whose best overall response is either CR, PR, or SD.

Time from first documented response (CR or PR) until documented disease progression or death, whichever occurs first.

Incidence, nature, and severity of adverse events graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Determination of changes in PROs with Functional Assessment of Cancer Therapy for patients with ovarian cancer (FACT-O) questionnaire

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi	NCT06161272	Ovarian Cancer High Grade Sero... Primary Periton... Fallopian Tube ...	Fluzoparib Fluzoparib+Apat...	18 Years - 75 Years	Guangxi Medical University
Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer	NCT01336231	Metastatic Kidn...		18 Years -	Centre Francois Baclesse
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer	NCT06063070	Ovarian Cancer High Grade Sero... High Grade Endo... Primary Periton... Fallopian-tube ...	Fluzoparib Caps... Bevacizumab	18 Years -	Sun Yat-sen University
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer	NCT05494580	Ovarian Cancer Ovarian Carcino... Platinum-resist... Fallopian Tube ... Primary Periton...	Pamiparib Surufatinib	18 Years - 75 Years	Sun Yat-sen University
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi	NCT06161272	Ovarian Cancer High Grade Sero... Primary Periton... Fallopian Tube ...	Fluzoparib Fluzoparib+Apat...	18 Years - 75 Years	Guangxi Medical University
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer	NCT06063070	Ovarian Cancer High Grade Sero... High Grade Endo... Primary Periton... Fallopian-tube ...	Fluzoparib Caps... Bevacizumab	18 Years -	Sun Yat-sen University

Spots Global Cancer Trial Database for antiangiogenic agents